Alaunos Therapeutics Temettü

Temettü kriter kontrolleri 0/6

Alaunos Therapeutics şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

Geri Alım Getirisi

Toplam Hissedar Getirisi	0%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü güncellemeleri

Güncelleme yok

Recent updates

Ziopharm: Waiting On FYE 2021 For Further Clinical Data On TCR-T/CAR-T Therapies

Jun 19

ZIOPHARM records sharpest gain in nearly four months

Jun 09

Will ZIOPHARM Oncology (NASDAQ:ZIOP) Spend Its Cash Wisely?

May 11

ZIOPHARM Oncology, Inc. 2021 Q1 - Results - Earnings Call Presentation

May 07

How Much Of ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Do Institutions Own?

Mar 09

We're Hopeful That ZIOPHARM Oncology (NASDAQ:ZIOP) Will Use Its Cash Wisely

Jan 15

ZioPharm highlights upcoming catalysts, says current cash runway into mid-2022

Jan 14

Ziopharm Oncology to test non-viral CAR-T in leukemia and lymphoma patients

Dec 21

Activist holder wins Ziopharm Oncology board seats

Dec 17

Ziopharm Oncology CFO to step down

Dec 14

What Is The Ownership Structure Like For ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP)?

Nov 23

Ziopharm says WaterMill’s nominees lack experience, White Rock backs proposal on board reconstitution

Nov 20

ZIOPHARM Oncology, Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 06

Ziopharm Oncology thumbs down on investor's call for board seats

Nov 02

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: TCRT şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: TCRT şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Alaunos Therapeutics Piyasaya Karşı Temettü Getirisi

TCRT temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (TCRT)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.5%
Sektör Ortalaması (Biotechs)	2.2%
Analist tahmini (TCRT) (3 yıla kadar)	n/a

Önemli Temettü: TCRT şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, TCRT şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: TCRT şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: TCRT herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Alaunos Therapeutics Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

Recent updates

Alaunos Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Alaunos Therapeutics, Inc. Appoints Dale Curtis Hogue, Jr. as Interim Chief Executive Officer

Alaunos Therapeutics, Inc. Appoints Dale Curtis Hogue as Director

Alaunos Therapeutics, Inc. Announces the Resignation of Mary Thistle as Member of the Board of Directors

Alaunos Therapeutics Receives a Staff Delisting Determination Letter from the Listing Qualifications Department

Nasdaq Approves Transfer of the Listing of the Common Stock of Alaunos Therapeutics from the Nasdaq Global Select Market to the Nasdaq Capital Market

Alaunos Therapeutics Announces Presentation At the 2Nd Hawaii Global Summit on Thoracic Malignancies

Alaunos Therapeutics to Present Early Data from TCR-T Library Phase 1/2 Trial at 2023 American Society of Clinical Oncology Annual Meeting

Alaunos Therapeutics, Inc. to Report Q1, 2023 Results on May 10, 2023

Forecast to breakeven in 2025

Price target decreased to US$3.75

Alaunos Therapeutics Receives A Deficiency Letter from Nasdaq Regarding Minimum Bid Price Requirement

Independent Director recently bought US$813k worth of stock

Alaunos Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $15 million.

Alaunos Therapeutics, Inc. has completed a Follow-on Equity Offering.

High number of new and inexperienced directors

Health Check: How Prudently Does Alaunos Therapeutics (NASDAQ:TCRT) Use Debt?

Alaunos Therapeutics, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Alaunos wins bullish view at Wells Fargo on promise of cell therapy technology

Alaunos Therapeutics, Inc. Highlights Data from TCR-T Library Phase 1/2 Trial at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference

Alaunos posts 51% tumor reduction for lung cancer therapy

Alaunos sheds 52% ahead of data readout for T-cell therapy platform

Alaunos Therapeutics Announces Early Clinical Data Showing Objective Clinical Response Using Its TCR-T Cell Therapy

Price target increased to US$4.20

Alaunos Therapeutics: Keep An Eye On Upcoming TCR-T Solid Tumor Study Data

Alaunos Therapeutics to Present at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference

Alaunos Therapeutics GAAP EPS of -$0.05 beats by $0.02

Alaunos Therapeutics, Inc. to Report Q2, 2022 Results on Aug 15, 2022

Is Alaunos Therapeutics (NASDAQ:TCRT) Weighed On By Its Debt Load?

Price target decreased to US$3.70

Alaunos Therapeutics, Inc. to Report Q1, 2022 Results on May 16, 2022

Alaunos Therapeutics, Inc. Doses First Patient in TCR-T Library Phase 1/2 trial for the Treatment of Patients with Solid Tumors

High number of new and inexperienced directors

Is Alaunos Therapeutics (NASDAQ:TCRT) Using Debt Sensibly?

ZIOPHARM Oncology, Inc.(NasdaqGS:TCRT) dropped from NASDAQ Composite Index

Consensus forecasts updated

Consensus forecasts updated

ZIOPHARM Oncology, Inc. Announces Operational Progress

Is ZIOPHARM Oncology (NASDAQ:ZIOP) A Risky Investment?

Price target decreased to US$4.60

High number of new directors

ZIOPHARM Oncology, Inc. announced delayed 10-Q filing

ZIOPHARM Oncology, Inc.(NasdaqGS:ZIOP) dropped from Russell 3000E Value Index

Ziopharm: Waiting On FYE 2021 For Further Clinical Data On TCR-T/CAR-T Therapies

ZIOPHARM records sharpest gain in nearly four months

Chief Legal Officer & Secretary has left the company

Price target decreased to US$5.08

Will ZIOPHARM Oncology (NASDAQ:ZIOP) Spend Its Cash Wisely?

Price target decreased to US$5.08

ZIOPHARM Oncology, Inc. 2021 Q1 - Results - Earnings Call Presentation

How Much Of ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Do Institutions Own?

CEO & Director Laurence James Cooper has left the company

Ziopharm Oncology, Inc. Receives IND Clearance by the U.S. FDA for Its TCR-T Trial Utilizing Six "Hotspot" TCRs from Its Library

Ziopharm Oncology, Inc. Appoints Timothy Cunningham Interim Chief Financial Officer

ZIOPHARM Oncology, Inc. to Report Q4, 2020 Results on Feb 25, 2021

Ziopharm Oncology, Inc. Announces Election of Robert Postma to Board of Directors

New 90-day high: US$4.24

Ziopharm Oncology Inc. Announces Executive Changes

We're Hopeful That ZIOPHARM Oncology (NASDAQ:ZIOP) Will Use Its Cash Wisely

ZioPharm highlights upcoming catalysts, says current cash runway into mid-2022

New 90-day high: US$3.16

CEO & Director notifies of intention to sell stock

Ziopharm Oncology Announces Clearance of Taiwan’s First IND of Non-viral CAR-T for the Treatment of Relapsed CD19+ Leukemias and Lymphomas

Ziopharm Oncology to test non-viral CAR-T in leukemia and lymphoma patients

ZIOPHARM Oncology, Inc. Announces Executive Changes

Activist holder wins Ziopharm Oncology board seats

Ziopharm Oncology, Inc. Announces Resignation of Satyavrat Shukla as CFO

New 90-day high: US$3.09

Ziopharm Oncology CFO to step down

Egan-Jones Recommends Against Electing Dissident’s Full Slate of Nominees to Ziopharm Oncology, Inc. Board

Ziopharm Oncology, Inc. Accepts the Resignation of Elan Ezickson as Director

What Is The Ownership Structure Like For ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP)?

Ziopharm says WaterMill’s nominees lack experience, White Rock backs proposal on board reconstitution

Ziopharm Oncology Presents Encouraging Clinical Data for Controlled Il-12 for the Treatment of Glioblastoma and Dipg At the 2020 Society for Neuro-Oncology Annual Meeting

Ziopharm Oncology, Inc. Appoints Raffaele Baffa as Chief Medical Officer